Clinical cases of Kasabaсh-Merritt syndrome in adult patients: 616-006.03:616-005.1:616.155.294

Abstract

Summary. Kasabach-Merritt syndrome (KMS) is a rare disease characterized by a combination of vascular tumor (hemangioma) and changes in laboratory tests — deep thrombocytopenia, hypofibrinogenemia, consumptive coagulopathy and increased D-dimer level. Diagnostics of KMS presents certain difficulties and based not only on the identification of characteristic clinical and labo- ratory features, but also on the results of histological examination of a vascular tumor. We report two rare clinical cases of KMS in adult patients and ways of therapeutic strategy. Treatment analysis showed that surgical therapy was highly riskily and did not result in improvement of the laboratory blood parameters, while the use of drug therapy was effective and safe.

References:

1. Melikyan A.L., Pustovaya E.I., Egorova E.K. et al. Differential diag- nosis of thrombocytopenias. Onkogematologiya. 2017;12(1):78–87. (In Russ.). DOI: 10.17650/1818–8346–2017–12–1–78–87. 

2. Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune throm- bocytopenic purpura of adults and children: Report from an international working group. Blood. 2009;113(11):2386–93. DOI: 10.1182/blood-2008–07–162503. 

3. Mazurov A.V., Khaspekova S.G., Vasiliev S.A. Diagnostics of throm- Terapevticheskij arhiv. 2018;90(7):4–13. (In Russ.). DOI: 10.26442/terarkh20189074–13. 

4. Kasabach H.H. Сapillary hemangioma with extensive pur- pura. Am J Dis Child. 1940;59(5):1063–70. DOI: 10.1001/arch- pedi.1940.01990160135009. 

5. Blei F. ISSVA classification of vascular anomalies. In: Congenital Vascular Malformations. Eds. Y.W. Kim, B.B. Lee, W. Yakes, Y.S. Do. Springer, Berlin, Heidelberg, 2017. 47–50. Available at: https://link. com/chapter/10.1007/978–3–662–46709–1_8. 

6. O’Rafferty C., O’Regan G.M., Irvine A. D., Smith O. P. Recent advances in the pathobiology and management of Kasabach- Merritt phenomenon. Br J Haematol. 2015;171(1):38–51. DOI: 10.1111/bjh.13557. 

7. Drolet B.A., Esterly N.B., Frieden I.J. Hemangiomas in children. N Engl J Med. 1999;341(3):173–81. DOI: 10.1056/NEJM199907153410307. 

8. Sarkar M., Mulliken J.B., Kozakewich H.P. et al. Thrombocytope- nic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg. 1997;100(6):1377–86. 
DOI: 10.1097/00006534–199711000–00001. 

9. Ketchum W. A., Lin-Hurtubise K.M., Ochmanek E. et al. Management of symptomatic hepatic “mega” hemangioma. Hawaii J Med Public Health. 2019;78(4):128–31.
10. Folkman J. Proceedings: tumor angiogenesis factor. Cancer Res. 1974;34(8):2109–13.
11. Kim H.S. Assignment of the human basic fibroblast growth factor gene FGF2 to chromosome 4 band q26 by radiation hybrid map- Cytogenet Cell Genet. 1998;83(1–2):73. DOI: 10.1159/000015129.
12. Dosquet C., Coudert M.C., Wassef M. et al. Importance of bFGF (“basic fibroblast growth factor”) for diagnosis and treatment of hemangiomas. Ann Dermatol Venereol. 1998;125(5):313–6. [Arti- cle in French].
13. Spitzer D., Krainz R., Graf A.H. et al. Pregnancy after ovarian stimulation and intrauterine insemination in a woman with caver- nous macrohemangioma of the liver. A case report. J Reprod Med. 1997;42(12):809–12.
14. R., Kligerman S., Levi J. et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg. 2001;67(2):173–8.

15. Brizel H.E., Raccuglia G. Giant hemangioma with thrombocy- topenia. Radioisotopic demonstration of platelet sequestration. Blood. 1965;26(6):751–64.
16. Lyons L.L., North P.E., Mac-Moune Lai F. et al. Kaposiform heman- gioendothelioma: a study of 33 cases emphasizing its patho- logic, immunophenotypic, and biologic uniqueness from juve- nile hemangioma. Am J Surg Pathol. 2004;28(5):559–68. DOI: 10.1097/00000478–200405000–00001.
17. Suzuki-Inoue K., Kato Y., Inoue O. et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activa- tion, by cancer cells. J Biol Chem. 2007;282(36):25993–6001. DOI: 10.1074/jbc.M702327200.
18. Aslan A., Meyer zu Vilsendorf A., Kleine M. et al. Adult Kasabach- Merritt syndrome due to hepatic giant hemangioma. Case Rep Gastroenterol. 2009;3(3):306–12. DOI: 10.1159/000242420.
19. Zhuang B.-W., Li W., Chen Z.-F. et al. Multiple cavernous heman- giomas of the lung and liver mimicking metastasis: A case report and literature review. Medicine (Baltimore). 2018;97(51):e13509. DOI: 10.1097/MD.0000000000013509.
20. Sugo H., Sekine Y., Miyano S. et al. Hepatic sclerosing hemangi- 
oma with predominance of the sclerosed area mimicking a bili- ary cystadenocarcinoma. Case Reports Hepatol. 2018;2018:7353170. DOI: 10.1155/2018/7353170. 

21. Gruenberger T. Giant hemangioma of the liver presenting with abdominal compartment syndrome: A case report. Eur Surg. 2005;37(1):57–8. DOI: 10.1007/s10353–004–0124–1. 

22. Imperiale A., Greget M., Chabrier G. et al. Solitary hepatic metastasis from medullary thyroid carcinoma mimicking atypical hemangioma. Clin Nucl Med. 2010;35(6):434–7. DOI: 10.1097/RLU.0b013e3181db4e45. 

23. Farges O., Daradkeh S., Bismuth H. Cavernous hemangiomas of the liver: Are there any indications for resection. World J Surg. 1995;19(1):19–24. DOI: 10.1007/BF00316974. 

24. Özden I., Emre A., Alper A. et al. Long-term results of surgery for liver hemangiomas. Arch Surg. 2000;135(8):978–81. DOI: 10.1001/archsurg.135.8.978. 

25. Buell J.F., Tranchart H., Cannon R., Dagher I. Management of benign hepatic tumors. Surg Clin North Am. 2010;90(4):719–35. DOI: 10.1016/j.suc.2010.04.006. 

26. Di Carlo I., Sofia M., Toro A. Does the psychological request of the patient justify the surgery for hepatic hemangioma? Hepatogas- troenterology. 2005;52:657–61. 

27. Meguro M., Soejima Y., Taketomi A. et al. Living donor liver trans- plantation in a patient with giant hepatic hemangioma compli- cated by Kasabach-Merritt syndrome: report of a case. Surg Today. 2008;38(5):463–8. DOI: 10.1007/s00595–007–3623–4. 

28. Mitchell A., Adams L.A., MacQuillan G. et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangi- Liver Transplant. 2008;14(2):210–3. DOI: 10.1002/lt.21417. 

29. M.,SandhuM.,LalP.,BalC.S.Roleofradiotherapyin cavernous hemangioma liver. Indian J Gastroenterol. 1995;14(3):95–8. 

30. Hashimoto M., Sugawara M., Ishiyama K. et al. Reduction in the size of a hepatic haemangioma after chemotherapy. Liver Int. 2008;28(7):1043–4. DOI: 10.1111/j.1478–3231.2007.01638.x.
31. Huang Y.-H., Zhou D.-B., Han B. et al. Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vin- cristine, and prednisone. J Int Med Res. 2019;47(4):1810–4. DOI: 10.1177/0300060519830242.
32. Lackner H., Karastaneva A., Schwinger W. et al. Sirolimus for the treatment of children with various complicated vascular ano- malies. Eur J Pediatr. 2015;174(12):1579–84. DOI: 10.1007/s00431– 015–2572-y.
33. Adams D.M., Trenor C.C., Hammill A.M. et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257. DOI: 10.1542/peds.2015–3257.
34. Rodriguez V., Lee A., Witman P.M., Anderson P.A. Kasabach- Merritt phenomenon: Case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol. 2009;31(7):522– 6. DOI: 10.1097/MPH.0b013e3181a71830.
35. Léauté-Labrèze C., De La Roque E.D., Hubiche T. et al. Pro- pranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–51. DOI: 10.1056/NEJMc0708819.
36. Talaat A.A., Elbasiouny M.S., Elgendy D.S., Elwakil T.F. Propran- olol treatment of infantile hemangioma: clinical and radiologic J Pediatr Surg. 2012;47(4):707–14. DOI: 10.1016/j.jped- surg.2011.10.058.
37. Bertrand J., McCuaig C., Dubois J. et al. Propranolol versus pred- nisone in the treatment of infantile hemangiomas: a retrospec- tive comparative study. Pediatr Dermatol. 2011;28(6):649–54. DOI: 1111/j.1525–1470.2011.01551.x.
38. Dai Y., Hou F., Buckmiller L. et al. Decreased eNOS protein expression in involuting and propranolol-treated hemangio- mas. Arch Otolaryngol Head Neck Surg. 2012;138(2):177–82. DOI: 10.1001/archoto.2011.1096.